TroyGould Represents LIXTE Biotechnology Holdings in $1.05 Million Offering Priced At-the-Market Under Nasdaq Rules

TroyGould acted as legal counsel for LIXTE Biotechnology Holdings, Inc. in a $1.05 million offering priced at-the-market under Nasdaq rules that closed on February 13, 2025.  H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.  LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies that trades under the ticker symbols “LIXT” and “LIXTW” on the Nasdaq Capital Market. David Ficksman acted as the advising attorney for the company.  For more information, see press release.

 

About TroyGould

Celebrating over 50 years of success as one of Southern California’s leading business law firms, TroyGould is recognized in the U.S. and abroad for its success in helping both U.S. and non-U.S entities and individuals achieve their business goals.  The firm’s transactional and litigation clients range from emerging companies to middle-market and Fortune 500 companies across a diverse set of industries including technology, life sciences, healthcare, entertainment/media, renewable energy, manufacturing, food and beverage, real estate and consumer products. For more information, visit TroyGould.com.